| Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer (NCT03901118) | Chipscreen Biosciences, Ltd. | 2019-07-01 |
| The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons (NCT03538665) | University of Alabama at Birmingham | 2019-07-01 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) (NCT03992131) | pharmaand GmbH | 2019-06-28 |
| Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors (NCT04234113) | SOTIO Biotech AG | 2019-06-13 |
| A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. (NCT03840200) | Hoffmann-La Roche | 2019-06-12 |
| Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers (NCT04626895) | Medstar Health Research Institute | 2019-06-04 |
| Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors (NCT03776630) | Assistance Publique - Hôpitaux de Paris | 2019-05-23 |
| Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures (NCT04849858) | University of California, Irvine | 2019-05-20 |
| Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (NCT03430700) | University College, London | 2019-05-16 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) (NCT03842982) | Centre Oscar Lambret | 2019-05-03 |
| A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients (NCT03863860) | Jiangsu HengRui Medicine Co., Ltd. | 2019-04-30 |
| A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (NCT03872947) | Toray Industries, Inc | 2019-04-26 |
| Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer (NCT03924882) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2019-04-25 |
| MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer (NCT03916679) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2019-04-20 |
| Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy (NCT03837327) | Venn Biosciences Corporation | 2019-04-16 |
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (NCT03907852) | TCR2 Therapeutics | 2019-04-15 |
| MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer (NCT03799913) | Zhejiang University | 2019-04-10 |
| MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour (NCT03934827) | Imperial College London | 2019-04-10 |
| Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 (NCT03644459) | Lynkcell Inc. | 2019-04-03 |
| NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. (NCT03752216) | ARCAGY/ GINECO GROUP | 2019-04-03 |
| The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance (NCT03846856) | Hillel Yaffe Medical Center | 2019-04-01 |
| Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) (NCT03940196) | NovoCure Ltd. | 2019-03-22 |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (NCT03860272) | Agenus Inc. | 2019-03-20 |
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) (NCT03657043) | Seagen Inc. | 2019-03-20 |
| HIPEC After Initial CRS in Patients Who Have Received NACT (NCT03540017) | Northwell Health | 2019-03-12 |
| Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response (NCT03831230) | Centre Francois Baclesse | 2019-03-07 |
| Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer (NCT03704467) | EMD Serono Research & Development Institute, Inc. | 2019-03-04 |
| Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer (NCT03818282) | Huazhong University of Science and Technology | 2019-03-01 |
| Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (NCT03797326) | Merck Sharp & Dohme LLC | 2019-02-12 |
| Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit? (NCT05448586) | Instituto de Investigación Hospital Universitario La Paz | 2019-02-02 |
| Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers (NCT03748186) | Sutro Biopharma, Inc. | 2019-02-01 |
| A Phase 1 Study of [225Ac]-FPI-1434 Injection (NCT03746431) | Fusion Pharmaceuticals Inc. | 2019-01-17 |
| A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine (NCT03854110) | Persevere Therapeutics Inc. | 2019-01-14 |
| A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer (NCT03895788) | Hunan Cancer Hospital | 2019-01-14 |
| A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer (NCT03695380) | Hoffmann-La Roche | 2019-01-09 |
| 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer (NCT03790423) | Rigshospitalet, Denmark | 2019-01-03 |
| STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands (NCT04470921) | Radboud University Medical Center | 2019-01-01 |
| MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii (NCT04053114) | Institut Bergonié | 2019-01-01 |
| Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer (NCT03759587) | Takeda | 2018-12-28 |
| Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer (NCT03759600) | Takeda | 2018-12-26 |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors (NCT03836352) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2018-12-21 |
| Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (NCT03689192) | Herlev Hospital | 2018-12-17 |
| Continued Access to RXDX-105 (NCT03784378) | Memorial Sloan Kettering Cancer Center | 2018-12-14 |
| BR55 in Characterization of Ovarian Lesions (NCT03493464) | Bracco Diagnostics, Inc | 2018-12-13 |
| Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer (NCT03639246) | Aravive, Inc. | 2018-12-06 |
| Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer (NCT03596281) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-12-05 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors (NCT03641287) | University of Washington | 2018-12-05 |
| Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients (NCT03787056) | Hospices Civils de Lyon | 2018-12-04 |
| European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer (NCT03783949) | Universitaire Ziekenhuizen KU Leuven | 2018-11-30 |
| Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer (NCT03738319) | Lei Li | 2018-11-10 |
| Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (NCT03621982) | ADC Therapeutics S.A. | 2018-11-09 |
| Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing (NCT04823871) | Paul Speiser, Prof.MD, | 2018-11-01 |
| Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors (NCT03755739) | Second Affiliated Hospital of Guangzhou Medical University | 2018-11-01 |
| Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells (NCT03634501) | Xuanwu Hospital, Beijing | 2018-10-26 |
| MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03585764) | University of Pennsylvania | 2018-10-24 |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (NCT03719326) | Arcus Biosciences, Inc. | 2018-10-15 |
| Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer (NCT03742713) | Cristal Therapeutics | 2018-10-01 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (NCT03648489) | Imperial College London | 2018-09-21 |
| COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (NCT03667716) | Compugen Ltd | 2018-09-06 |
| Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer (NCT03412877) | National Cancer Institute (NCI) | 2018-09-06 |
| 4FMFES-PET Imaging of Endometrial and Ovarian Cancers (NCT04823065) | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 2018-09-01 |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (NCT03593681) | Boston Scientific Corporation | 2018-08-27 |
| Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors (NCT03662204) | Exact Sciences Corporation | 2018-08-23 |
| A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03635489) | Hoffmann-La Roche | 2018-08-15 |
| Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) (NCT03532139) | Beth Israel Deaconess Medical Center | 2018-07-25 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer (NCT03364673) | Dana-Farber Cancer Institute | 2018-07-20 |
| Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) (NCT03642132) | Pfizer | 2018-07-19 |
| A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. (NCT03549000) | Novartis Pharmaceuticals | 2018-07-18 |
| Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer (NCT03587129) | First Affiliated Hospital of Harbin Medical University | 2018-07-10 |
| BEACON - ABC in Recurrent Platinum Resistant HGSOC (NCT03363867) | Peter MacCallum Cancer Centre, Australia | 2018-07-10 |
| Open Label Immunotherapy Trial for Ovarian Cancer (NCT03556566) | Immunitor LLC | 2018-07-01 |
| Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma (NCT03470805) | Grupo Español de Investigación en Cáncer de Ovario | 2018-06-21 |
| Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO (NCT06917469) | Centro di Riferimento Oncologico - Aviano | 2018-06-20 |
| Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (NCT03394885) | Duke University | 2018-06-19 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (NCT03278717) | University College, London | 2018-06-15 |
| 3D Prediction of Patient-Specific Response (NCT03561207) | KIYATEC | 2018-06-11 |
| Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer (NCT03539328) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2018-06-01 |
| Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy (NCT03547375) | Anhui Provincial Hospital | 2018-06-01 |
| Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors (NCT03490669) | AstraZeneca | 2018-05-21 |
| Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation) (NCT03505307) | AstraZeneca | 2018-05-21 |
| Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (NCT03519230) | BeiGene | 2018-05-14 |
| Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer (NCT07648745) | Prof Gordon Jayson | 2018-05-14 |
| Trial in Patients With Relapsed Ovarian Cancer (NCT03267589) | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2018-05-14 |
| IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (NCT03378297) | Haukeland University Hospital | 2018-05-04 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451) | Corvus Pharmaceuticals, Inc. | 2018-04-25 |
| A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. (NCT03763123) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2018-04-24 |
| Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study (NCT03464201) | Grupo Español de Tumores Huérfanos e Infrecuentes | 2018-04-13 |
| Clinical Impact of Dedicated MR Staging of Ovarian Cancer (NCT03399344) | The Netherlands Cancer Institute | 2018-04-13 |
| Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer (NCT03300843) | National Cancer Institute (NCI) | 2018-04-11 |
| A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer (NCT03414047) | Eli Lilly and Company | 2018-04-10 |
| A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer (NCT03509636) | Jiangsu HengRui Medicine Co., Ltd. | 2018-04-04 |
| Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer (NCT03246074) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-04-03 |
| Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer (NCT03410784) | National Cancer Institute, Naples | 2018-04-01 |
| PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. (NCT03283943) | British Columbia Cancer Agency | 2018-04-01 |
| FPA150 in Patients With Advanced Solid Tumors (NCT03514121) | Five Prime Therapeutics, Inc. | 2018-03-27 |
| Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India (NCT03471572) | AstraZeneca | 2018-03-22 |
| Diaphragmatic Resection And Gynecological Ovarian Neoplasm (NCT03543462) | Catholic University of the Sacred Heart | 2018-03-20 |